Topic,Count,Name,Representation,Representative_Docs
-1,6,-1_total cost_fair market_contingent consideration_net product,"['total cost', 'fair market', 'contingent consideration', 'net product', '', '', '', '', '', '']","['We expect total cost of goods sold to be in the range of $75 million to $80 million', 'For Iclusig, we expect net product revenue to be in the range of $60 million to $65 million', 'In addition, we expect a change in the fair market value of a contingent consideration for the Iclusig royalty liability to be in the range of $30 million to $35 million']"
0,46,0_ongoing expense_cash stock_total revenue_cash expense,"['ongoing expense', 'cash stock', 'total revenue', 'cash expense', 'upfront cash', 'significant portion', 'previous slide', 'left hand', 'new indications', 'extensive product']","['As I mentioned earlier, the increase in our SG&A expense year-over-year includes a full year of expense for our recently acquired European operations versus seven months in 2016. We expect total non-cash expense related to employee equity awards to be in the range of $130 million to $140 million', 'We expect SG&A expense to be in the range of $340 million to $360 million, including non-cash expense related to employee equity awards', 'We therefore expect these one-time expense items to be approximately $205 million and we expect ongoing R&D expense to be in the range of $785 million to $835 million, including non-cash expense related to employee equity awards']"
1,15,1_net product_net adjustment_net sales_,"['net product', 'net adjustment', 'net sales', '', '', '', '', '', '', '']","['Jakafi net sales and the amortization of acquired product rights, related to the Iclusig product acquisition', 'This was comprised of $853 million in Jakafi net product revenue, $30 million in Iclusig net product revenue, $111 million in Jakavi royalties from Novartis and $113 million in contract revenue', 'This was comprised of $238 million in Jakafi net product revenue, $13 million in Iclusig net product revenue, $33 million in Jakavi royalties from Novartis and $43 million in contract revenue, including a milestone paid to us by Novartis, related to pricing approval of Jakavi for PV']"
